Eyelash-boosting drug gets FDA panel approval

Glaucoma medication may be safe, effective route to long, full lashes

Is your skin getting the care it needs? Amy Robach gets the answers in a special Web-only series. Watch the show

Skin and beauty videos

Sammy Sosa’s skin lightened?
Nov. 9: Baseball slugger Sammy Sosa shocked the crowd when he showed up at a Las Vegas event with much lighter skin. Is he doing some kind of “skin cleansing,” as some have suggested? Dr. Nancy Snyderman talks with msnbc.com’s Courtney Hazlett and dermatologist Dr. Lynn McKinley Grant.

Sammy Sosa's skin under scrutiny

Procedure offers 'cool' way to fight fat

Keep your skin healthy this fall

Barbie has cankles?

updated 3:10 p.m. ET Dec. 5, 2008

WASHINGTON - A panel of government experts said Friday a glaucoma drug from Allergan appears to be a safe and effective way to make eyelashes longer and fuller.

Allergan, which makes Botox anti-wrinkle injections, has asked the Food and Drug Administration to approve its Lumigan formula to enhance eyelashes.

The agency's panel of outside eye and skin specialists voted unanimously that the drug's benefits outweighed its risks. However, the same panel voted 5-3 with one abstention that Allergan should be required to conduct follow-up studies to address questions about the drug's use among certain patient groups.

Story continues below ↓

advertisement | your ad here

"I'm worried about off-label, nonsupervised use of this medication, and I'm concerned teenagers might use it three or four times a day instead of once," said Dr. Marijean Miller, an ophthalmologist with the Children's National Medical Center in Washington.

Other experts noted that only one African-American patient was included in company trials and said Allergan should be required to show the drug's effectiveness in that population.

The FDA is not required to follow the panel's advice, though it normally does. The agency is expected to make a decision on the drug in mid-2009.

The drug is already marketed to treat eye conditions stemming from glaucoma. In studies for that treatment, researchers first noticed the drug seemed to stimulate eyelash growth.

Could ‘Latisse’ post $500 million a year in sales?
Irvine, Calif.-based Allergan plans to market the drug under the brand name Latisse, if it is approved as a cosmetic treatment.

A study conducted by Allergan showed once-daily application with the formula significantly increased prominence of lashes after four months. The study also met its secondary goals of increasing eyelash length, thickness and darkness.

Click for related content

FDA says glaucoma drug enhances eyelashes
Vegas doctor convicted of using Botox knockoff
FDA receives 930 reports of wrinkle-filler issues

Allergan has estimated that Latisse could garner more than $500 million in sales annually, however, analysts are more conservative about the product's short-term potential. Cowen & Co. analyst Ken Cacciatore projected in a research note that Latisse would reach $15 million in sales for 2009 and $30 million in 2010.

Shares of Allergan rose $1.36, or 3.7 percent, to $37.78.